Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT02997228 |
TitleCombination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study | 阶段
第三阶段
|
Date Added 2016-12-20 |
地点
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
暂停
|
药物
Atezolizumab, fluorouracil, Leucovorin, oxaliplatin |
标签
MSI-H/ MMRd
|
| NCT ID NCT02988960 |
TitleA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2016-12-12 |
地点
California, United States
Illinois, United States Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States 澳大利亚 加拿大 法国 日本 大韩民国 西班牙 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
ABBV-181, ABBV-927, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT02925234 |
Title药物再发现方案（DRUP 试验） | 阶段
第二阶段
|
Date Added 2016-10-05 |
地点
荷兰
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02888743 |
TitleDurvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | 阶段
第二阶段
|
Date Added 2016-09-05 |
地点
Arizona, United States
California, United States Connecticut, United States Florida, United States Georgia, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Virginia, United States Wisconsin, United States 加拿大 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
durvalumab, Tremelimumab |
标签
MSS/ MMRp
|
| NCT ID NCT02886585 |
TitlePembrolizumab In Central Nervous System Metastases | 阶段
第二阶段
|
Date Added 2016-09-01 |
地点
Massachusetts, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT02869217 |
TitleStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | 阶段
第 1 阶段
|
Date Added 2016-08-16 |
地点
加拿大
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Cyclophosphamide, Fludarabine, TBI-1301 |
标签
MSS/ MMRp
|
| NCT ID NCT02864485 |
Title活体肝移植治疗无法切除的结直肠癌肝转移灶 | 阶段
不适用
|
Date Added 2016-08-12 |
地点
加拿大
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02856425 |
TitleTrial Of Pembrolizumab And Nintedanib | 阶段
第 1 阶段
|
Date Added 2016-08-04 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
Nintedanib, Pembrolizumab, Keytruda, Ofev, Vargatef |
标签
MSS/ MMRp
|
| NCT ID NCT02693535 |
TitleTAPUR：测试食品药品管理局（FDA）批准的针对晚期癌症患者肿瘤基因特定异常的药物的使用情况 | 阶段
第二阶段
|
Date Added 2016-02-26 |
地点
Alabama, United States
Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02675946 |
TitleCGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | 阶段
第 1 阶段
|
Date Added 2016-02-05 |
地点
California, United States
Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maryland, United States Massachusetts, United States Nebraska, United States New Jersey, United States North Carolina, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States 台湾 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
cetuximab, CGX1321, encorafenib, Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
